Unii-33y9anm545 Pazopanib Hydrochloride Pazopanib HCl Intermediate Pazopanib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Pazopanib
• Product Name: Pazopanib
• Name: Pazopanib Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 635702-64-6
• Mf: C21h23n7o2s.Clh
• MW: 473.987
• Boiling Point: >290c
• Einecs: 619-728-0
• Transport Package: Negotiable
• Specification: Negotiable
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Unii-33y9anm545 Pazopanib Hydrochloride Pazopanib Hcl Intermediate Pazopanib

Product Description

 

Product Datails

 

Product name	Pazopanib
Cas number	635702-64-6
Apperance	White Powder
Boiling Point	290°
MF	C21H23N7O2S.ClH
MW	473.987

Pazopanib is researched and developed by a GlaxoSmithKline ,it is a novel oral vascular generation inhibitor which may interfere stubborn tumor survival and new blood vessels generation growth needed .Targeting vascular endothelial receptor (VEGFR),it works by inhibiting angiogenesis of tumor blood supply.      it is suitable for advanced renal cell carcinoma ( a discovery of cancer cells in the renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC) treatment.

Application&Function

 

Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity.         Pazopanib selectively inhibits vascular endothelial receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived  receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.
Pazopanib Indications:
1.    FDA-approved for patients with advanced kidney cancer.
2.    FDA-approved for patients with advanced soft tissue sarcoma (STS) who have previously received chemotherapy.

Specification